Sarepta Therapeutics, Inc. – LSE:0L35.L
Sarepta Therapeutics stock price today
Sarepta Therapeutics stock price monthly change
Sarepta Therapeutics stock price quarterly change
Sarepta Therapeutics stock price yearly change
Sarepta Therapeutics key metrics
Market Cap | 11.38B |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | 0.13 |
Revenue | 1.40B |
EBITDA | -52.88M |
Income | 16.89M |
Revenue Q/Q | 63.10% |
Revenue Y/Y | 43.82% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | -3.77% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeSarepta Therapeutics stock price history
Sarepta Therapeutics stock forecast
Sarepta Therapeutics financial statements
| Jun 2023 | 261.23M | -23.94M | -9.16% |
|---|---|---|---|
| Sep 2023 | 331.81M | -40.93M | -12.34% |
| Dec 2023 | 396.78M | 45.65M | 11.51% |
| Mar 2024 | 413.46M | 36.11M | 8.74% |
| Mar 2024 | 413.46M | 36.11M | 8.74% |
|---|---|---|---|
| Sep 2025 | 1.07B | 538.64M | 50.07% |
| Oct 2025 | 893.67M | 333.02M | 37.26% |
| Dec 2025 | 881.07M | 327.27M | 37.14% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 3125890000 | 2.38B | 76.28% |
|---|---|---|---|
| Sep 2023 | 3109707000 | 2.34B | 75.42% |
| Dec 2023 | 3264576000 | 2.40B | 73.68% |
| Mar 2024 | 3224385000 | 2.26B | 70.19% |
| Jun 2023 | -122.23M | 96.63M | 5.86M |
|---|---|---|---|
| Sep 2023 | -114.70M | -210.57M | 15.40M |
| Dec 2023 | -54.65M | -64.35M | 1.94M |
| Mar 2024 | -242.07M | 218.79M | 22.14M |
Sarepta Therapeutics alternative data
| Aug 2023 | 1,162 |
|---|---|
| Sep 2023 | 1,162 |
| Oct 2023 | 1,162 |
| Nov 2023 | 1,162 |
| Dec 2023 | 1,162 |
| Jan 2024 | 1,162 |
| Feb 2024 | 1,162 |
| Mar 2024 | 1,314 |
| Apr 2024 | 1,314 |
| May 2024 | 1,314 |
| Jun 2024 | 1,314 |
| Jul 2024 | 1,314 |
Sarepta Therapeutics other data
| Patent |
|---|
Application Filling date: 11 Oct 2021 Issue date: 18 Aug 2022 |
Application Filling date: 12 Jun 2019 Issue date: 11 Aug 2022 |
Application Filling date: 16 Apr 2020 Issue date: 23 Jun 2022 |
Application Filling date: 15 Dec 2021 Issue date: 2 Jun 2022 |
Application Filling date: 25 Mar 2020 Issue date: 19 May 2022 |
Application Filling date: 10 Nov 2021 Issue date: 28 Apr 2022 |
Application Filling date: 23 Dec 2020 Issue date: 14 Apr 2022 |
Application SYSTEMIC DELIVERY OF ADENO-ASSOCIATED VIRUS VECTOR EXPRESSING GAMMA-SARCOGLYCAN AND THE TREATMENT OF MUSCULAR DYSTROPHY Filling date: 7 Sep 2021 Issue date: 24 Mar 2022 |
Application Filling date: 16 Aug 2021 Issue date: 10 Mar 2022 |
Application Filling date: 19 Apr 2021 Issue date: 24 Feb 2022 |
| Insider | Compensation |
|---|---|
| Mr. Douglas S. Ingram (1963) Pres, Chief Executive Officer & Director | $1,390,000 |
| Dr. Gilmore O'Neill M.D. (1965) Executive Vice President of R&D and Chief Medical Officer | $933,330 |
Mr. David Tyronne Howton Jr. (1972) Executive Vice President, Gen. Counsel & Corporation Sec. | $731,800 |
Mr. William F. Ciambrone (1964) Executive Vice President of Technical Operations | $438,010 |
| Dr. Louise Rodino-Klapac Ph.D. Senior Vice President of Gene Therapy | |
Dr. Diane L. Berry Senior Vice President of Global Health Policy and Gov. & Patient Affairs | |
| Dr. Edward M. Kaye Advisor | |
| Mr. Joseph Bratica Controller, Vice President and Interim Principal Financial & Accounting Officer | |
Mr. Ian M. Estepan Senior Vice President of Corporation Affairs & Chief of Staff | |
Ms. Joan Nickerson M.B.A. Senior Vice President of HR |
-
What's the price of Sarepta Therapeutics stock today?
One share of Sarepta Therapeutics stock can currently be purchased for approximately $90.83.
-
When is Sarepta Therapeutics's next earnings date?
Unfortunately, Sarepta Therapeutics's (0L35.L) next earnings date is currently unknown.
-
Does Sarepta Therapeutics pay dividends?
No, Sarepta Therapeutics does not pay dividends.
-
How much money does Sarepta Therapeutics make?
Sarepta Therapeutics has a market capitalization of 11.38B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 33.26% to 1.24B US dollars.
-
What is Sarepta Therapeutics's stock symbol?
Sarepta Therapeutics, Inc. is traded on the LSE under the ticker symbol "0L35.L".
-
What is Sarepta Therapeutics's primary industry?
Company operates in the Healthcare sector and Medical - Pharmaceuticals industry.
-
How do i buy shares of Sarepta Therapeutics?
Shares of Sarepta Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Sarepta Therapeutics's key executives?
Sarepta Therapeutics's management team includes the following people:
- Mr. Douglas S. Ingram Pres, Chief Executive Officer & Director(age: 62, pay: $1,390,000)
- Dr. Gilmore O'Neill M.D. Executive Vice President of R&D and Chief Medical Officer(age: 60, pay: $933,330)
- Mr. David Tyronne Howton Jr. Executive Vice President, Gen. Counsel & Corporation Sec.(age: 53, pay: $731,800)
- Mr. William F. Ciambrone Executive Vice President of Technical Operations(age: 61, pay: $438,010)
- Dr. Louise Rodino-Klapac Ph.D. Senior Vice President of Gene Therapy
- Dr. Diane L. Berry Senior Vice President of Global Health Policy and Gov. & Patient Affairs
- Dr. Edward M. Kaye Advisor
- Mr. Joseph Bratica Controller, Vice President and Interim Principal Financial & Accounting Officer
- Mr. Ian M. Estepan Senior Vice President of Corporation Affairs & Chief of Staff
- Ms. Joan Nickerson M.B.A. Senior Vice President of HR
-
How many employees does Sarepta Therapeutics have?
As Jul 2024, Sarepta Therapeutics employs 1,314 workers.
-
When Sarepta Therapeutics went public?
Sarepta Therapeutics, Inc. is publicly traded company for more then 7 years since IPO on 29 Jan 2018.
-
What is Sarepta Therapeutics's official website?
The official website for Sarepta Therapeutics is sarepta.com.
-
Where are Sarepta Therapeutics's headquarters?
Sarepta Therapeutics is headquartered at 215 First Street, Cambridge, MA.
-
How can i contact Sarepta Therapeutics?
Sarepta Therapeutics's mailing address is 215 First Street, Cambridge, MA and company can be reached via phone at +61 72744000.
Sarepta Therapeutics company profile:
Sarepta Therapeutics, Inc.
sarepta.comLSE
1,314
Medical - Pharmaceuticals
Healthcare
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Cambridge, MA 02142
:
ISIN: US8036071004
:
